Disc Medicine
Update in progressIRON (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Disc Medicine, Inc. is a clinical‑stage biopharmaceutical company focused on discovering, developing, and commercializing treatments for serious hematologic diseases in the United States. Its portfolio targets red blood cell formation and function by modulating heme biosynthesis and iron homeostasis. Lead programs include bitopertin for erythropoietic porphyrias and Diamond‑Blackfan anemia; DISC‑0974 for anemia in myelofibrosis and CKD; DISC‑3405 for polycythemia vera. Founded 2017; based in Watertown, MA.
Company score
- Sentiment
- 0.40
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.08
- Governance
- 0.19
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.06
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.23
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!